Comparison · NCT03015129-sae
Durvalubmab vs Durvalubmab + Tremelimumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Durvalubmab vs Durvalubmab + Tremelimumab: serious adverse events. Trial comparisons, record NCT03015129-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03015129-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.325 | 0.201 | 0.48 | wilson | |
| Risk in group 2 | 0.175 | 0.0875 | 0.319 | wilson | |
| Risk difference, group 1 minus group 2 | 0.15 | -0.0405 | 0.328 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.86 | 0.828 | 4.16 | log | |
| Odds ratio, group 1 over group 2 | 2.27 | 0.794 | 6.49 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Durvalubmab than on Durvalubmab + Tremelimumab | 6.67 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Durvalubmab | Patients will receive intravenous infusion of durvalumab 1500mg Fixed Dose every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.~Durvalumab | 13 | 40 | EG000 |
| Group 2 | Durvalubmab + Tremelimumab | Patients will receive 1500mg Flat Dose durvalubmab via intravenous infusion every 4 weeks for up to 4 cycles and 75mg tremelimumab via intravenous infusion every 4 weeks for up to 4 cycles, and then continue 1500mg Fixed Dose durvalumab every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.~Durvalumab~Tremelimumab | 7 | 40 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 1 year
Source ClinicalTrials.gov
Trial
- Title
- A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
- NCT number
- NCT03015129
- Phases
- PHASE2
- Conditions
- Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent, Endometrial Carcinoma, Recurrent
- Interventions
- Durvalumab, Tremelimumab
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Results first posted
- 2024-02-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03015129?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03015129-sae